bi-4SCAR CD19/22 T
/ SZGIMI
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 27, 2022
CD19/22 Bi-specific CAR-T Cell Therapy
(clinicaltrials.gov)
- P1/2 | N=60 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute
CAR T-Cell Therapy • New P1/2 trial • Oncology • CD19 • CD22
1 to 1
Of
1
Go to page
1